FDMT - Company ID 0001650648
The table below shows 4D Molecular Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $3.05M | $90.00K | $15.00K | $14.00K | $3.00K | $5.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A |
4D Molecular Therapeutics, Inc. reported annual revenue of $85.21M for fiscal year 2025. That is up 230194.6% from $37.00K in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $6.99M (FY 2019) to $85.21M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $11.69M |
| $11.84M |
| $11.52M |
| $12.94M |
| $12.65M |
| $10.60M |
| Operating income | -$73.62M | -$61.19M | -$59.46M | -$53.62M | -$51.13M | -$42.46M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$68.76M | -$56.88M | -$54.66M | -$47.97M | -$43.84M | -$34.95M |
| EPS (diluted) | -$1.01 | -$1.01 | -$0.98 | -$0.86 | -$0.79 | -$0.63 |